【摘要】 目的探索奥氮平所致代谢综合征(MS)与血清白细胞介素-6(IL-6)水平及认知功能的关系。方法 2015年1月—2017年12月在上海交通大学医学院附属精神卫生中心、广东省韶关市粤北第三人民医院、浙江省金华市第二医院和浙江省温州市康宁医院招募242例单药使用奥氮平治疗2年以上的精神分裂症患者。根据是否伴MS分为MS组105例,非MS组137例。采用阳性和阴性症状量表(PANSS)评定精神分裂症患者临床症状,重复性神经心理状态测验(RBANS)评定认知功能,采用酶联免疫吸附试验检测血清IL-6水平。结果两组患者奥氮平使用时间和使用剂量比较,差异有高度统计学意义(P <0.01)。MS组PANSS阴性症状分高于非MS组,差异有统计学意义(P <0.05)。MS组RBANS即刻记忆、注意、延时记忆评分以及总分均低于非MS组,差异有统计学意义(P <0.05)。MS组血清IL-6水平高于非MS组,差异有统计学意义(P <0.05)。患者血清IL-6水平与RBANS注意评分呈负相关(r=-0.16,P <0.05)。结论奥氮平所致MS引起的IL-6升高可能造成精神分裂症患者继发性认知损害。更多还原

【Abstract】 Objective To explore the relationship between metabolic syndrome(MS) caused by Olanzapine and serum interleukin-6(IL-6) levels and cognitive function.Methods From January 2015 to December 2017,a total of 242 cases who were treated with Schizophrenia for more than two years of single-drug use were recruited at Shanghai Mental Health Center of Shanghai Jiao Tong University School of Medicine,Yuebei Third People’ s Hospital,Jinhua Second Hospital,and Wenzhou Kangning Hospital in Zhejiang Province.According to whether they were associated with MS,they were divided into 105 cases in MS group and 137 cases in non-MS group.The positive and negative symptom scale(PANSS) was used to assess the clinical symptoms of patients with schizophrenia,while the repeatable battery for the assessment of neuropsychological status(RBANS) was used to assess cognitive function,and the serum IL-6 levels were measured by enzyme-linked immunosorbent assay.Results There were highly statistically significant differences in the use time and dose of Olanzapine between the two groups(P <0.01).The score of PANSS negative symptoms in the MS group was higher than that in the non-MS group,and the difference was statistically significant(P <0.05).The RBANS immediate memory,attention,delayed memory and total scores of the MS group were lower than those of the non-MS group,and the differences were statistically significant(P <0.05).The level of serum IL-6 in the MS group was higher than that in the non-MS group,and the difference was statistically significant(P <0.05).The serum IL-6 levels of the patients were negatively correlated with the RBANS attention score(r=-0.16,P <0.05).Conclusion The increase of IL-6 caused by MS caused by Olanzapine may cause secondary cognitive impairment in patients with schizophrenia.更多还原